Virtual Biopsy by Using Artificial Intelligence-based Multimodal Modeling of Binational Mammography Data.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
03 2023
Historique:
pubmed: 26 10 2022
medline: 25 2 2023
entrez: 25 10 2022
Statut: ppublish

Résumé

Background Computational models based on artificial intelligence (AI) are increasingly used to diagnose malignant breast lesions. However, assessment from radiologic images of the specific pathologic lesion subtypes, as detailed in the results of biopsy procedures, remains a challenge. Purpose To develop an AI-based model to identify breast lesion subtypes with mammograms and linked electronic health records labeled with histopathologic information. Materials and Methods In this retrospective study, 26 569 images were collected in 9234 women who underwent digital mammography to pretrain the algorithms. The training data included individuals who had at least 1 year of clinical and imaging history followed by biopsy-based histopathologic diagnosis from March 2013 to November 2018. A model that combined convolutional neural networks with supervised learning algorithms was independently trained to make breast lesion predictions with data from 2120 women in Israel and 1642 women in the United States. Results were reported using the area under the receiver operating characteristic curve (AUC) with the 95% DeLong approach to estimate CIs. Significance was tested with bootstrapping. Results The Israeli model was validated in 456 women and tested in 441 women (mean age, 51 years ± 11 [SD]). The U.S. model was validated in 350 women and tested in 344 women (mean age, 60 years ± 12). For predicting malignancy in the test sets (consisting of 220 Israeli patient examinations and 126 U.S. patient examinations with ductal carcinoma in situ or invasive cancer), the algorithms obtained an AUC of 0.88 (95% CI: 0.85, 0.91) and 0.80 (95% CI: 0.74, 0.85) for Israeli and U.S. patients, respectively (

Identifiants

pubmed: 36283109
doi: 10.1148/radiol.220027
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e220027

Auteurs

Vesna Barros (V)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Tal Tlusty (T)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Ella Barkan (E)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Efrat Hexter (E)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

David Gruen (D)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Michal Guindy (M)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Michal Rosen-Zvi (M)

From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH